---
title: "Bone Biologics Q2 net loss widens 4.48% to $773,702"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295977109.md"
description: "Bone Biologics reported a Q2 net loss of $773,702, a 4.48% increase year-over-year. Operating losses widened by 8.02% to $808,106 due to an 8.02% rise in total operating expenses. R&D costs surged 61.13% to $308,747 for protein shelf-life development, while G&A costs decreased 10.26%. Cash holdings stood at $4.03 million as of June 30, 2026, bolstered by a July 2026 private placement raising approximately $2.7 million."
datetime: "2026-08-14T21:06:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295977109.md)
  - [en](https://longbridge.com/en/news/295977109.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295977109.md)
---

# Bone Biologics Q2 net loss widens 4.48% to $773,702

-   Bone Biologics posted a Q2 net loss of USD 773,702, widening 4.48% from a year earlier. \* Operating loss widened 8.02% to USD 808,106 as total operating expenses rose 8.02% to USD 808,106. \* R&D expense climbed 61.13% to USD 308,747 due to development work to extend protein shelf-life. \* G&A costs fell 10.26% to USD 499,359; interest income more than doubled to USD 34,512. \* Cash totaled USD 4.03 million at June 30, 2026; a July 2026 private placement raised about USD 2.7 million net. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038482), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BBLG.US](https://longbridge.com/en/quote/BBLG.US.md)
- [BBLGW.US](https://longbridge.com/en/quote/BBLGW.US.md)

## Related News & Research

- [Bone Biologics extends rhNELL-1 shelf life to 32 months as NB1 spine fusion trial advances](https://longbridge.com/en/news/295662468.md)
- [3 Next-Gen AI Stocks That 3G Capital Bought in Q2](https://longbridge.com/en/news/296496173.md)
- [Algorhythm Holdings Reports Second Quarter 2026 Financial Results](https://longbridge.com/en/news/296124832.md)
- [RGA EVP, Global Chief Risk Officer Jonathan Porter disposes of 8,589 shares worth $2.12 million](https://longbridge.com/en/news/296156346.md)
- [RenaissanceRe EVP, Chief Portfolio Officer Curtis Ross sells 5,000 common shares for $1.63 million](https://longbridge.com/en/news/296141969.md)